Business Description
Adagene Inc
ISIN : US0053291078
Share Class Description:
FRA:978: ADRDescription
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.6 | |||||
| Equity-to-Asset | 0.56 | |||||
| Debt-to-Equity | 0.37 | |||||
| Debt-to-EBITDA | -0.66 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.51 | |||||
| Beneish M-Score | -1.98 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 189.9 | |||||
| 3-Year EBITDA Growth Rate | 29.7 | |||||
| 3-Year EPS without NRI Growth Rate | 52.9 | |||||
| 3-Year FCF Growth Rate | 2.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -48.68 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.97 | |||||
| 9-Day RSI | 44.48 | |||||
| 14-Day RSI | 44.08 | |||||
| 6-1 Month Momentum % | 13.16 | |||||
| 12-1 Month Momentum % | 104.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.5 | |||||
| Quick Ratio | 2.5 | |||||
| Cash Ratio | 2.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.5 | |||||
| Shareholder Yield % | 5.14 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -4533.46 | |||||
| Net Margin % | -3903.19 | |||||
| FCF Margin % | -3498.8 | |||||
| ROE % | -45.51 | |||||
| ROA % | -27.16 | |||||
| ROIC % | -245.86 | |||||
| ROC (Joel Greenblatt) % | -1475.05 | |||||
| ROCE % | -39.08 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 116.84 | |||||
| PB Ratio | 1.74 | |||||
| Price-to-Tangible-Book | 1.74 | |||||
| EV-to-EBIT | -0.74 | |||||
| EV-to-EBITDA | -0.74 | |||||
| EV-to-Revenue | 28.64 | |||||
| EV-to-FCF | -0.82 | |||||
| Price-to-Net-Current-Asset-Value | 1.81 | |||||
| Price-to-Net-Cash | 1.91 | |||||
| Earnings Yield (Greenblatt) % | -135.26 | |||||
| FCF Yield % | -29.04 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Adagene Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.748 | ||
| EPS (TTM) (€) | -0.669 | ||
| Beta | -0.41 | ||
| Volatility % | 120.97 | ||
| 14-Day RSI | 44.08 | ||
| 14-Day ATR (€) | 0.116538 | ||
| 20-Day SMA (€) | 2.3065 | ||
| 12-1 Month Momentum % | 104.76 | ||
| 52-Week Range (€) | 1.27 - 3.66 | ||
| Shares Outstanding (Mil) | 44.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Adagene Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Adagene Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Adagene Inc Frequently Asked Questions
What is Adagene Inc(FRA:978)'s stock price today?
The current price of FRA:978 is €2.12. The 52 week high of FRA:978 is €3.66 and 52 week low is €1.27.
When is next earnings date of Adagene Inc(FRA:978)?
The next earnings date of Adagene Inc(FRA:978) is 2025-03-28 Est..
Does Adagene Inc(FRA:978) pay dividends? If so, how much?
Adagene Inc(FRA:978) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers